{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:01:19Z","timestamp":1774987279138,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008635","name":"University of Texas Health Science Center at San Antonio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008635","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.09.003","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:19:36Z","timestamp":1759205976000},"page":"992-999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post Hoc Analyses of DKD Clinical Trials in Ethnic Minorities (Asian, Hispanic, Black) Narrative Review"],"prefix":"10.1016","volume":"47","author":[{"given":"Li-Li","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Coca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel H.","family":"Fantaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca M.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-9418","authenticated-orcid":false,"given":"Carolina","family":"Solis-Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.09.003_bib0001","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.2040-1124.2011.00131.x","article-title":"Pathogenesis of diabetic nephropathy","volume":"2","author":"Cao","year":"2011","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1412874","article-title":"The diabetes cardiovascular outcomes trials and racial and ethnic minority enrollment: impact, barriers, and potential solutions","volume":"12","author":"Sinclair","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0003","unstructured":"NIH. Diversity and inclusion in clinical trials. 2023. www.nimhd.nih.gov2023. (accessed November 26, 2023)."},{"key":"10.1016\/j.clinthera.2025.09.003_bib0004","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0005","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0006","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0007","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0009","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0010","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0012","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/oby.24042","article-title":"Efficacy and safety of semaglutide 2.4\u2009mg by race and ethnicity: a post hoc analysis of three randomized controlled trials","volume":"32","author":"Rubino","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0013","series-title":"Centers for Disease Control and Prevention","year":"2023"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0014","series-title":"National Diabetes Statistics Report website","year":"2024"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0015","first-page":"153","article-title":"Race, racism, and the policy of 21st century medicine","volume":"94","author":"Keeys","year":"2021","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.ajkd.2018.02.354","article-title":"CKD and ESRD in US Hispanics","volume":"73","author":"Desai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0017","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/dom.14251","article-title":"Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: an Asian perspective and expert recommendations","volume":"23","author":"Khoo","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0018","series-title":"Global, Regional, and Ethnic Differences in Diabetic Nephropathy","first-page":"33","author":"Ameh","year":"2019"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0020","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.2337\/dc20-0495","article-title":"Sustained lower incidence of diabetes-related end-stage kidney disease among American Indians and AK Natives, Blacks, and Hispanics in the U.S., 2000\u20132016","volume":"43","author":"Burrows","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(16)30324-2","article-title":"Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes","volume":"5","author":"Hoppe","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100730","article-title":"Finerenone in black patients with type 2 diabetes and CKD: a post hoc analysis of the Pooled FIDELIO-DKD and FIGARO-DKD trials","author":"Flack","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0023","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials","volume":"5","author":"Carson","year":"1999","journal-title":"J Card Fail"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0024","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0025","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1741-7015-11-141","article-title":"Why do hypertensive patients of African ancestry respond better to calciumblockers and diuretics than to ACE inhibitors and \u03b2-adrenergic blockers? A systematic review","volume":"11","author":"Brewster","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0027","series-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","article-title":"The national academies collection: reports funded by National Institutes of Health","year":"2022"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0028","series-title":"ISN\u2013Global Kidney Health Atlas: A report by the International Society of Nephrology: An Assessment of Global Kidney Health Care Status focussing on Capacity, Availability, Accessibility, Affordability and Outcomes of Kidney Disease","author":"Bello","year":"2023"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0029","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00125-023-05997-2","article-title":"Racial\/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the ACCORD trial","volume":"66","author":"Cromer","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0030","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00125-022-05736-z","article-title":"Exploring ethnic representativeness in diabetes clinical trial enrolment from 2000 to 2020: a chronological survey","volume":"65","author":"Li","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0031","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00125-023-06052-w","article-title":"Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review","volume":"67","author":"Ahmed","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100594","article-title":"Race, sex, and kidney disease trial participation","volume":"5","author":"Alahamadi","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0033","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0034","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0035","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0036","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1093\/ndt\/gfq189","article-title":"Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients","volume":"25","author":"Barbour","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0037","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jama.2021.13304","article-title":"Updated guidance on the reporting of race and ethnicity in medical and science journals","volume":"326","author":"Flanagin","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0038","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100704","article-title":"Finerenone in Hispanic patients with CKD and type 2 diabetes: a post hoc FIDELITY analysis","author":"Rosas","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0040","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.ekir.2023.02.437","article-title":"WCN23-0618 cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: prespecified sub-analysis from fidelity","volume":"8","author":"Koya","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10877","article-title":"Effectiveness and safety of dapagliflozin for black and white patients with chronic kidney disease in North and South America","volume":"6","author":"Vart","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0042","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/dom.14539","article-title":"Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial","volume":"24","author":"Weir","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0043","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ekir.2022.01.1060","article-title":"Efficacy and safety of dapagliflozin in patients with CKD across major geographic regions","volume":"7","author":"Vart","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0044","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s10157-024-02489-4","article-title":"Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY","volume":"28","author":"Nangaku","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jdi.13624","article-title":"Renal, cardiovascular and safety outcomes of canagliflozin in patients with type\u20092 diabetes and nephropathy in East and South-East Asian countries: results from the canagliflozin and renal events in diabetes with established nephropathy clinical evaluatio","volume":"13","author":"Wada","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0046","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000531997","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes: the FIDELIO-DKD subgroup from China","volume":"9","author":"Zhang","year":"2023","journal-title":"Kidney Dis"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0047","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/dom.13805","article-title":"Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis","volume":"21","author":"Mishriky","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0048","article-title":"Racial, ethnic and regional differences in the effect of sodium\u2013glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials","author":"Kunutsor","year":"2023","journal-title":"J R Soc Med"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.003_bib0049","first-page":"227","article-title":"Cardiorenal benefits of finerenone in different races and kidney function in patients with chronic kidney disease","volume":"14","author":"Li","year":"2024","journal-title":"Cardiorenal Med"},{"issue":"9\u201310","key":"10.1016\/j.clinthera.2025.09.003_bib0050","first-page":"1","article-title":"Cardiorenal outcomes with finerenone in asian patients with chronic kidney disease and type 2 diabetes: a FIDELIO-DKD post hoc analysis","volume":"54","author":"Koya","year":"2023","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.1016\/j.clinthera.2025.09.003_bib0051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026791","article-title":"Ethnic variations in cardiovascular and renal outcomes from newer glucose-lowering drugs: a meta-analysis of randomized outcome trials","volume":"12","author":"Tang","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0052","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jdi.13355","article-title":"Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from global burden of disease 2017","volume":"12","author":"Li","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017605","article-title":"Impact of a patient\u2019s baseline risk on the relative benefit and harm of a preventive treatment strategy: applying trial results in clinical decision making","volume":"11","author":"De Vries","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0054","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s40615-016-0332-y","article-title":"Barriers and strategies for recruitment of racial and ethnic minorities: perspectives from neurological clinical research coordinators","volume":"4","author":"Haley","year":"2017","journal-title":"J Racial Ethn Health Disparities"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-7683-3","article-title":"Aggregation of Asian-American subgroups masks meaningful differences in health and health risks among Asian ethnicities: an electronic health record based cohort study","volume":"19","author":"Gordon","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0056","doi-asserted-by":"crossref","first-page":"1532372","DOI":"10.3389\/fpubh.2025.1532372","article-title":"The impact of social determinants of health on chronic kidney disease risk: evidence from the CHARLS study","volume":"13","author":"Li","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0057","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0058","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2025.09.003_bib0059","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical Pr","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182500308X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182500308X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:55:01Z","timestamp":1774947301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182500308X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S014929182500308X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post Hoc Analyses of DKD Clinical Trials in Ethnic Minorities (Asian, Hispanic, Black) Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}